{"pub": "marketwatch", "url": "https://marketwatch.com/story/bausch-files-suit-against-novartis-unit-sandoz-for-infringing-patents-on-xifaxan-550-mg-tablets-2019-10-01", "downloaded_at": "2019-10-01 11:44:22.202245+00:00", "title": "Bausch files suit against Novartis unit Sandoz for infringing patents on Xifaxan 550 mg tablets", "language": "en", "text": "Bausch Health Cos. Inc. BHC, +0.69% said Tuesday it is filing a lawsuit against Novartis AG unit Sandoz NVS, -0.57% for the infringement of patents protecting its Xifaxan 550 mg tablets, a treatment for irritable bowel syndrome. The company, formerly called Valeant, said Sandoz infringed 14 patents when it filed an abbreviated new drug application for Xifaxan 550 mg tablets. \"Bausch Health remains confident in the strength of the XIFAXAN patents and will continue to vigorously defend its intellectual property,\" the company said in a statement. Bausch shares fell 1.1% in premarket trade, while Novartis ADRs were down 0.8%.", "description": "Bausch Health Cos. Inc. said Tuesday it is filing a lawsuit against Novartis AG unit Sandoz for the infringement of patents protecting its Xifaxan 550 mg...", "authors": ["Ciara Linnane", "Corporate News Editor"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-01"}